ESR1 and breast carcinoma: Aberrant PI3K/Akt/mTOR signaling is also seen in cells with FGFR1 overexpression and amplification [26], and response to the PI3K inhibitor alpelisib is reduced in ER+/PIK3CA-mutant breast cancer cells that overexpress FGFR1 [35].